Literature DB >> 2732121

The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients.

A Boccazzi1, M Langer, M Mandelli, A M Ranzi, R Urso.   

Abstract

The pharmacokinetics of aztreonam were studied in ten critically ill intubated patients with lower respiratory tract infections. Serum and urinary concentrations of the drug and its penetration into bronchial secretions after a 2-g intravenous bolus were measured. Using a two-compartment linear model a terminal half-life of 1.87 + 0.46 h was determined. No interpatient differences were found for half-life values, AUC or volume of distribution, except in the case of one obese patient. The greatest variability was observed in the clearance values, and in particular the extrarenal clearance which ranged from 0.3 to 9.6 1/h. Maximum concentrations in bronchial secretions were reached very quickly in the 2 h after drug administration, with a range of 4.8-18.7 mg/l. No accumulation of aztreonam after repeated doses was detected.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2732121     DOI: 10.1093/jac/23.3.401

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Drug treatment of pneumonia in the hospital. What are the choices?

Authors:  M Aoun; J Klastersky
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.

Authors:  Cherie Chu; Louis Lteif; Nicole Young
Journal:  Hawaii J Med Public Health       Date:  2017-06

3.  Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model.

Authors:  E J Ernst; S Hashimoto; J Guglielmo; T Sawa; J F Pittet; H Kropp; J J Jackson; J P Wiener-Kronish
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Therapeutic Drug Monitoring of Prolonged Infusion Aztreonam for Multi-Drug Resistant Pseudomonas aeruginosa: A Case Report.

Authors:  Jeffrey J Cies; Richard J LaCoursiere; Wayne S Moore; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Nov-Dec

Review 5.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

6.  Liquid Chromatography Mass Spectrometry Detection of Antibiotic Agents in Sputum from Persons with Cystic Fibrosis.

Authors:  Tara Gallagher; Stefan Riedel; Joseph Kapcia; Lindsay J Caverly; Lisa Carmody; Linda M Kalikin; Junnan Lu; Joann Phan; Matthew Gargus; Miki Kagawa; Simon W Leemans; Jason A Rothman; Felix Grun; John J LiPuma; Katrine L Whiteson
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

7.  Aztreonam pharmacokinetics in burn patients.

Authors:  L V Friedrich; R L White; M B Kays; D M Brundage; D Yarbrough
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

8.  Differential distributions in tissues and efficacies of aztreonam and ceftazidime and in vivo bacterial morphological changes following treatment.

Authors:  A Turcotte; M Simard; N J Morin; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of aztreonam. An update.

Authors:  H Mattie
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.